Tessa Romero
Stock Analyst at JP Morgan
(3.56)
# 626
Out of 4,829 analysts
58
Total ratings
39.53%
Success rate
9.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Maintains: Neutral | $18 → $17 | $12.56 | +35.35% | 5 | Mar 21, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $72 → $68 | $20.56 | +230.74% | 6 | Mar 5, 2025 | |
| UPB Upstream Bio | Initiates: Overweight | $38 | $9.50 | +300.00% | 1 | Nov 5, 2024 | |
| NMRA Neumora Therapeutics | Downgrades: Neutral | $18 → $15 | $0.69 | +2,066.06% | 4 | Nov 5, 2024 | |
| MCRB Seres Therapeutics | Downgrades: Underweight | n/a | $7.88 | - | 2 | Oct 24, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $18 → $31 | $32.46 | -4.50% | 5 | Oct 14, 2024 | |
| CYTK Cytokinetics | Maintains: Overweight | $65 → $71 | $32.13 | +120.98% | 4 | Sep 5, 2024 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Overweight | $32 → $29 | $5.85 | +395.73% | 3 | Aug 13, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Overweight | $30 → $31 | $14.82 | +109.18% | 8 | Aug 12, 2024 | |
| AGIO Agios Pharmaceuticals | Reinstates: Neutral | $46 | $29.14 | +57.86% | 6 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $25 | $17.52 | +42.69% | 6 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.63 | +660.46% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $4.07 | +71.99% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $55 | $35.85 | +53.42% | 2 | Apr 25, 2023 |
Dyne Therapeutics
Mar 21, 2025
Maintains: Neutral
Price Target: $18 → $17
Current: $12.56
Upside: +35.35%
Biohaven
Mar 5, 2025
Maintains: Overweight
Price Target: $72 → $68
Current: $20.56
Upside: +230.74%
Upstream Bio
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $9.50
Upside: +300.00%
Neumora Therapeutics
Nov 5, 2024
Downgrades: Neutral
Price Target: $18 → $15
Current: $0.69
Upside: +2,066.06%
Seres Therapeutics
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $7.88
Upside: -
Scholar Rock Holding
Oct 14, 2024
Maintains: Overweight
Price Target: $18 → $31
Current: $32.46
Upside: -4.50%
Cytokinetics
Sep 5, 2024
Maintains: Overweight
Price Target: $65 → $71
Current: $32.13
Upside: +120.98%
EyePoint Pharmaceuticals
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $5.85
Upside: +395.73%
Edgewise Therapeutics
Aug 12, 2024
Maintains: Overweight
Price Target: $30 → $31
Current: $14.82
Upside: +109.18%
Agios Pharmaceuticals
Jun 13, 2024
Reinstates: Neutral
Price Target: $46
Current: $29.14
Upside: +57.86%
Mar 25, 2024
Maintains: Overweight
Price Target: $29 → $25
Current: $17.52
Upside: +42.69%
Nov 28, 2023
Initiates: Overweight
Price Target: $20
Current: $2.63
Upside: +660.46%
Aug 22, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $4.07
Upside: +71.99%
Apr 25, 2023
Maintains: Overweight
Price Target: $54 → $55
Current: $35.85
Upside: +53.42%